Access and Affordability in the Age of GLP-1s
A Conversation with Stacie B. Dusetzina, PhD, Benedic N. Ippolito, PhD, MS, and Mark McClellan, MD, PhD, moderated by Norma B. Coe, PhD
GLP-1 drugs are rapidly reshaping the health care landscape. Their use for weight loss is growing, new oral formulations are entering the market, and indications for their use are expanding. At the same time, Medicare, Medicaid, and private insurers face growing pressure to determine how to cover these effective but costly treatments, prompting new delivery and payment models. As debates over access and affordability intensify, researchers are exploring new uses, suggesting further disruption may be on the horizon. This panel will examine the evolving GLP-1 policy landscape, with a focus on cost, access, and health system-wide implications.
Supported by the Charles C. Leighton, MD Memorial Fund.
Speakers

Stacie B. Dusetzina, PhD
Professor, Health Policy and Ingram Professor of Cancer Research, Vanderbilt University Medical Center

Benedic N. Ippolito, PhD, MS
Senior Fellow, American Enterprise Institute

Mark McClellan, MD, PhD
Director, Duke-Margolis Institute for Health Policy, Duke University

Norma B. Coe, PhD (moderator)
Professor, Medical Ethics and Health Policy, Perelman School of Medicine; Director of Research, Penn LDI; Co-Director, Health Economics Data Analyst Pool, Penn LDI
Panelist Disclosures
Mark McClellan is an independent board member for Alignment Health Care, Cigna, Johnson & Johnson, and PrognomIQ, and is an advisor for Arsenal Capital Group, Blackstone Life Sciences, and MITRE. He chairs the National Academy of Medicine’s Leadership Consortium: Collaboration for a Learning Health System, and co-chairs the Executive Forum of the Health Care Payment Learning and Action Network.